BioSpecifics Technologies Corp (BSTC)
(Delayed Data from NSDQ)
$66.72 USD
+0.21 (0.32%)
Updated May 3, 2019 04:00 PM ET
After-Market: $66.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.72 USD
+0.21 (0.32%)
Updated May 3, 2019 04:00 PM ET
After-Market: $66.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
BioSpecifics Technologies (BSTC) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
BioSpecifics (BSTC) delivered earnings and revenue surprises of 315.79% and 106.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: BioSpecifics Technologies (BSTC) Q3 Earnings Expected to Decline
by Zacks Equity Research
BioSpecifics (BSTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Endo (ENDP) Q3 Earnings & Sales Top Estimates, View Raised
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the third quarter. The company raises its annual outlook.
Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates
by Zacks Equity Research
The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.
Endo (ENDP) Gains on Deal to Acquire BioSpecifics for $540M
by Zacks Equity Research
Endo (ENDP) gains from the acquisition of commercial-stage biopharmaceutical company, BioSpecifics Technologies Corp.
The Truth About Market Timing - October 06, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
The Keys to Successfully Timing the Markets - September 15, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
The Keys to Successfully Timing the Markets - August 18, 2020
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
New Strong Sell Stocks for August 14th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Catalyst's (CPRX) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Catalyst (CPRX) beats both earnings and sales estimates in the second quarter of 2020.
BioSpecifics Technologies (BSTC) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
BioSpecifics (BSTC) delivered earnings and revenue surprises of 320.00% and 89.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate BioSpecifics Technologies (BSTC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BioSpecifics (BSTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
When Does Market Timing Actually Work? - July 29, 2020
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
IMV Catches Eye: Stock Jumps 10%
by Zacks Equity Research
IMV saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Cassava Sciences (SAVA) Jumps: Stock Rises 9.2%
by Zacks Equity Research
Cassava Sciences (SAVA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Timing the Market, Is it Possible? - July 07, 2020
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
The Truth About Market Timing - June 17, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
Zacks.com featured highlights include: BioSpecificsTechnologies, eXp World, Elbit Systems and KoninklijkeVopak
by Zacks Equity Research
Zacks.com featured highlights include: BioSpecificsTechnologies, eXp World, Elbit Systems and KoninklijkeVopak
4 Stocks With Rising Cash Flows to Beat Coronavirus Crisis
by Moumita C. Chattopadhyay
Cash is the lifeblood of any business, and provides vitality and strength to a company.
Is BioSpecifics Technologies (BSTC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (BSTC) Outperforming Other Medical Stocks This Year?
Timing the Market, Is it Possible? - April 28, 2020
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
New Strong Buy Stocks for April 23rd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Zacks.com featured highlights include: PJT Partners, CBIZ, BioSpecifics Technologies, eXp World and Gibraltar Industries
by Zacks Equity Research
Zacks.com featured highlights include: PJT Partners, CBIZ, BioSpecifics Technologies, eXp World and Gibraltar Industries
5 Stocks With Rising Cash Flows to Battle Coronavirus Crisis
by Moumita C. Chattopadhyay
Cash provides vitality and strength to a company. It holds the key to the company's existence, development and success, and can indeed be referred to as its lifeblood.
Zacks.com featured highlights include: Gibraltar Industries, CBIZ, Integer, BioSpecifics Technologies and DHT
by Zacks Equity Research
Zacks.com featured highlights include: Gibraltar Industries, CBIZ, Integer, BioSpecifics Technologies and DHT